Skip to main content
SpringerLink
Log in

The Use of Curcumin for the Treatment of Renal Disorders: A Systematic Review of Randomized Controlled Trials

  • Chapter
  • First Online:
Studies on Biomarkers and New Targets in Aging Research in Iran

Part of the book series: Advances in Experimental Medicine and Biology ((PMISB,volume 1291))

Abstract

Chronic kidney disease (CKD) is one of the significant causes of morbidity and mortality worldwide, which could develop and progress to end-stage renal disease. Increased inflammation and reduced antioxidant capacity commonly occur in CKD and hemodialysis patients. Curcumin is a natural bioactive compound with antioxidant and anti-inflammatory properties. This systematic review was undertaken with the main aim of assessing the effects of curcumin/turmeric supplementation on renal diseases based on clinical trials. A comprehensive search was performed in PubMed/MEDLINE, Scopus, ISI Web of Science, and Google Scholar from inception up to April 6, 2020 to identify clinical trials assessing the effects of curcumin or turmeric alone, or in combination with other herbs or nutrients on renal diseases. Twelve studies met the eligibility criteria. These randomized controlled trials (RCTs) comprised 631 patients with either chronic kidney diseases (CKD), hemodialysis, diabetic proteinuria and nephropathy, and lupus nephritis. Curcumin/turmeric supplementation had favorable effects on renal diseases, particularly in terms of inflammation and oxidative stress. However, with the exception for proteinuria, their impact on clinical parameters, such as blood urea nitrogen, creatinine, glomerular filtration rate (GFR), and serum albumin, was weak and not significant. No serious adverse effects were reported following curcumin/turmeric supplementation. Within the limitations of this review, it can be concluded that curcumin/turmeric supplementation might have some beneficial effects on inflammatory and oxidative stress parameters of patients but no considerable positive impact on clinical outcomes of kidney diseases, apart from proteinuria.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Hill NR, Fatoba ST, Oke JL, Hirst JA, O’Callaghan CA, Lasserson DS et al (2016) Global prevalence of chronic kidney disease–a systematic review and meta-analysis. PLoS One 11(7):e0158765. https://doi.org/10.1371/journal.pone.0158765

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Etgen T, Chonchol M, Forstl H, Sander D (2012) Chronic kidney disease and cognitive impairment: a systematic review and meta-analysis. Am J Nephrol 35(5):474–482

    Article  PubMed  Google Scholar 

  3. Perlman RL, Finkelstein FO, Liu L, Roys E, Kiser M, Eisele G et al (2005) Quality of life in chronic kidney disease (CKD): a cross-sectional analysis in the Renal Research Institute-CKD study. Am J Kidney Dis 45(4):658–666

    Article  PubMed  Google Scholar 

  4. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJ, Mann JF et al (2013) Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet 382(9889):339–352

    Article  PubMed  Google Scholar 

  5. Alebiosu C, Ayodele O (2005) The global burden of chronic kidney disease and the way forward. Ethn Dis 15(3):418

    CAS  PubMed  Google Scholar 

  6. Atkins RC (2005) The epidemiology of chronic kidney disease. Kidney Int 67:S14–S18

    Article  Google Scholar 

  7. Dandona P, Aljada A, Bandyopadhyay A (2004) Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 25(1):4–7

    Article  CAS  PubMed  Google Scholar 

  8. Haffner SM (2006) The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease. Am J Cardiol 97(2):3–11

    Article  CAS  Google Scholar 

  9. Manabe I (2011) Chronic inflammation links cardiovascular, metabolic and renal diseases. Circ J 75(12):2739–2748

    Article  CAS  PubMed  Google Scholar 

  10. Pawelec G, Goldeck D, Derhovanessian E (2014) Inflammation, ageing and chronic disease. Curr Opin Immunol 29:23–28

    Article  CAS  PubMed  Google Scholar 

  11. Akchurin M, Kaskel F (2015) Update on inflammation in chronic kidney disease. Blood Purif 39(1–3):84–92

    Article  CAS  PubMed  Google Scholar 

  12. Yao Q, Axelsson J, Stenvinkel P, Lindholm B (2004) Chronic systemic inflammation in dialysis patients: an update on causes and consequences. ASAIO J 50(6):lii–lvii. https://doi.org/10.1097/01.mat.0000147958.87989.eb

    Article  PubMed  Google Scholar 

  13. Forbes JM, Coughlan MT, Cooper ME (2008) Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 57(6):1446–1454

    Article  CAS  PubMed  Google Scholar 

  14. Small DM, Coombes JS, Bennett N, Johnson DW, Gobe GC (2012) Oxidative stress, anti-oxidant therapies and chronic kidney disease. Nephrology 17(4):311–321

    Article  CAS  PubMed  Google Scholar 

  15. Chandar J, Abitbol C, Montane B, Zilleruelo G (2007) Angiotensin blockade as sole treatment for proteinuric kidney disease in children. Nephrol Dial Transpl 22(5):1332–1337

    Article  CAS  Google Scholar 

  16. Alicic RZ, Tuttle KR (2014) Novel therapies for diabetic kidney disease. Adv Chronic Kidney Dis 21(2):121–133

    Article  PubMed  Google Scholar 

  17. Pandya V, Rao A, Chaudhary K (2015) Lipid abnormalities in kidney disease and management strategies. World J Nephrol 4(1):83

    Article  PubMed  PubMed Central  Google Scholar 

  18. Keane WF, Tomassini JE, Neff DR (2012) Lipid abnormalities in patients with chronic kidney disease: implications for the pathophysiology of atherosclerosis. J Atheroscler Thromb 20(2):123–133

    Article  PubMed  Google Scholar 

  19. Wanner C, Zimmermann J, Schwedler S, Metzger T (2002) Inflammation and cardiovascular risk in dialysis patients. Kidney Int 61:S99–S102

    Article  Google Scholar 

  20. Qureshi AR, Alvestrand A, Divino-Filho JC, Gutierrez A, Heimbürger O, Lindholm B et al (2002) Inflammation, malnutrition, and cardiac disease as predictors of mortality in hemodialysis patients. J Am Soc Nephrol 13(Suppl 1):S28–S36

    Article  PubMed  Google Scholar 

  21. Talebi S, Bagherniya M, Atkin SL, Askari G, Orafai HM, Sahebkar A (2020) The beneficial effects of nutraceuticals and natural products on small dense LDL levels, LDL particle number and LDL particle size: a clinical review. Lipids Health Dis 19(1):66. https://doi.org/10.1186/s12944-020-01250-6

    Article  PubMed  PubMed Central  Google Scholar 

  22. Bagherniya M, Nobili V, Blesso CN, Sahebkar A (2018) Medicinal plants and bioactive natural compounds in the treatment of non-alcoholic fatty liver disease: a clinical review. Pharmacol Res 130:213–240

    Article  CAS  PubMed  Google Scholar 

  23. Bagherniya M, Johnston TP, Sahebkar A (2020) Regulation of apolipoprotein B by natural products and nutraceuticals: a comprehensive review. Curr Med Chem. https://doi.org/10.2174/0929867327666200427092114. Online ahead of print

  24. Musabayane C (2012) The effects of medicinal plants on renal function and blood pressure in diabetes mellitus. Cardiovasc J Afr 23(8):462–468

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Iranshahi M, Sahebkar A, Hosseini ST, Takasaki M, Konoshima T, Tokuda H (2010) Cancer chemopreventive activity of diversin from Ferula diversivittata in vitro and in vivo. Phytomedicine 17(3–4):269–273

    Article  CAS  PubMed  Google Scholar 

  26. Kocaadam B, Şanlier N (2017) Curcumin, an active component of turmeric (Curcuma longa), and its effects on health. Crit Rev Food Sci Nutr 57(13):2889–2895

    Article  CAS  PubMed  Google Scholar 

  27. Ringman JM, Frautschy SA, Cole GM, Masterman DL, Cummings JL (2005) A potential role of the curry spice curcumin in Alzheimer’s disease. Curr Alzheimer Res 2(2):131–136

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Wongcharoen W, Phrommintikul A (2009) The protective role of curcumin in cardiovascular diseases. Int J Cardiol 133(2):145–151

    Article  PubMed  Google Scholar 

  29. Mollazadeh H, Cicero AFG, Blesso CN, Pirro M, Majeed M, Sahebkar A (2019) Immune modulation by curcumin: the role of interleukin-10. Crit Rev Food Sci Nutr 59(1):89–101

    Article  CAS  PubMed  Google Scholar 

  30. Hasanzadeh S, Read MI, Bland AR, Majeed M, Jamialahmadi T, Sahebkar A (2020) Curcumin: an inflammasome silencer. Pharmacol Res 159:104921. https://doi.org/10.1016/j.phrs.2020.104921. Epub 2020 May 25. PMID: 32464325

  31. Teymouri M, Pirro M, Johnston TP, Sahebkar A (2017) Curcumin as a multifaceted compound against human papilloma virus infection and cervical cancers: A review of chemistry, cellular, molecular, and preclinical features. BioFactors 43(3):331–346

    Google Scholar 

  32. Mohajeri M, Bianconi V, Ávila-Rodriguez MF, Barreto GE, Jamialahmadi T, Pirro M, Sahebkar A (2020) Curcumin: a phytochemical modulator of estrogens and androgens in tumors of the reproductive system. Pharmacol Res 156:104765. https://doi.org/10.1016/j.phrs.2020.104765. Epub 2020 Mar 23. PMID: 32217147

  33. Sahebkar A (2013) Why it is necessary to translate curcumin into clinical practice for the prevention and treatment of metabolic syndrome? BioFactors 39(2):197–208

    Article  CAS  PubMed  Google Scholar 

  34. Momtazi AA, Derosa G, Maffioli P, Banach M, Sahebkar A (2016) Role of microRNAs in the therapeutic effects of curcumin in non-cancer diseases. Mol Diagn Ther 20(4):335–345

    Article  CAS  PubMed  Google Scholar 

  35. Momtazi AA, Sahebkar A (2016) Difluorinated curcumin: a promising curcumin analogue with improved anti-tumor activity and pharmacokinetic profile. Curr Pharm Des 22(28):4386–4397

    Article  CAS  PubMed  Google Scholar 

  36. Bagheri H, Ghasemi F, Barreto GE, Rafiee R, Sathyapalan T, Sahebkar A (2020) Effects of curcumin on mitochondria in neurodegenerative diseases. Biofactors. 46(1):5–20. https://doi.org/10.1002/biof.1566. Epub 2019 Oct 3. PMID: 31580521

  37. Huang SJ, Huang J, Yan YB, Qiu J, Tan RQ, Liu Y et al (2020) The renoprotective effect of curcumin against cisplatin-induced acute kidney injury in mice: involvement of miR-181a/PTEN axis. Ren Fail 42(1):350–357

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Damiano S, Andretta E, Longobardi C, Prisco F, Paciello O, Squillacioti C et al (2020) Effects of curcumin on the renal toxicity induced by Ochratoxin A in rats. Antioxidants (Basel) 9(4):E332. https://doi.org/10.3390/antiox9040332

    Article  CAS  Google Scholar 

  39. Akomolafe SF, Olasehinde TA, Adewale OO, Ajayi OB (2020) Curcumin improves biomolecules associated with renal function and attenuates oxidative injury and histopathological changes in potassium-induced toxicity in rats. Kidney Biol Trace Elem. https://doi.org/10.1007/s12011-020-02113-y. Online ahead of print

  40. Hami M, Bigdeli A, Rajabi O, Salehi M (2019) The effect of curcumin in prevention of contrast nephropathy following coronary angiography or angioplasty in CKD patients. Iran J Kidney Dis 13(5):304–309

    PubMed  Google Scholar 

  41. Alvarenga L, Salarolli R, Cardozo LFMF, Santos RS, de Brito JS, Kemp JA et al (2020) Impact of curcumin supplementation on expression of inflammatory transcription factors in hemodialysis patients: a pilot randomized, double-blind, controlled study. Clin Nutr S0261-5614(20):30110–30112. https://doi.org/10.1016/j.clnu.2020.03.007. Online ahead of print

    Article  CAS  Google Scholar 

  42. Afshar GV, Rasmi Y, Yagmaye P, Khadem-Ansari MH, Makhdomi K, Rasooli J (2020) The effects of nano-curcumin supplementation on serum level of hs-CRP, adhesion molecules, and lipid profiles in hemodialysis patients, a randomized controlled clinical trial. Iran J Kidney Dis 14(1):52–61

    Google Scholar 

  43. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151(4):264–269

    Article  PubMed  Google Scholar 

  44. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17(1):1–12

    Article  CAS  PubMed  Google Scholar 

  45. Moher D, Cook D, Jadad A, Tugwell P, Moher M, Jones A et al (1999) Assessing the quality of reports of randomised trials: implications for the conduct of meta-analyses. Health Technol Assess 3(12):i–iv., 1–98

    Google Scholar 

  46. Jiménez-Osorio AS, García-Niño WR, González-Reyes S, Álvarez-Mejía AE, Guerra-León S, Salazar-Segovia J et al (2016) The effect of dietary supplementation with curcumin on redox status and Nrf2 activation in patients with nondiabetic or diabetic proteinuric chronic kidney disease: a pilot study. J Ren Nutr 26(4):237–244

    Article  PubMed  CAS  Google Scholar 

  47. Khajehdehi P, Pakfetrat M, Javidnia K, Azad F, Malekmakan L, Nasab MH et al (2011) Oral supplementation of turmeric attenuates proteinuria, transforming growth factor-β and interleukin-8 levels in patients with overt type 2 diabetic nephropathy: a randomized, double-blind and placebo-controlled study. Scand J Urol Nephrol 45(5):365–370

    Article  CAS  PubMed  Google Scholar 

  48. Khajehdehi P, Zanjaninejad B, Aflaki E, Nazarinia M, Azad F, Malekmakan L et al (2012) Oral supplementation of turmeric decreases proteinuria, hematuria, and systolic blood pressure in patients suffering from relapsing or refractory lupus nephritis: a randomized and placebo-controlled Study. J Ren Nutr 22(1):50–57

    Article  CAS  PubMed  Google Scholar 

  49. Moreillon JJ, Bowden RG, Deike E, Griggs J, Wilson R, Shelmadine B et al (2013) The use of an anti-inflammatory supplement in patients with chronic kidney disease. J Complement Integr Med 10(1):1–10

    Article  Google Scholar 

  50. Ortiz BOM, Preciado ARF, Emiliano JR, Garza SM, Rodríguez ER, de Alba Macías LA (2019) Recovery of bone and muscle mass in patients with chronic kidney disease and iron overload on hemodialysis and taking combined supplementation with curcumin and resveratrol. Clin Interv Aging 14:2055–2062

    Article  CAS  Google Scholar 

  51. Pakfetrat M, Akmali M, Malekmakan L, Dabaghimanesh M, Khorsand M (2015) Role of turmeric in oxidative modulation in end-stage renal disease patients. Hemodial Int 19(1):124–131

    Article  PubMed  Google Scholar 

  52. Pakfetrat M, Basiri F, Malekmakan L, Roozbeh J (2014) Effects of turmeric on uremic pruritus in end stage renal disease patients: a double-blind randomized clinical trial. J Nephrol 27(2):203–207

    Article  CAS  PubMed  Google Scholar 

  53. Samadian F, Dalili N, Gholi FPR, Fattah M, Malih N, Nafar M et al (2017) Evaluation of Curcumin's effect on inflammation in hemodialysis patients. Clin Nutr ESPEN 22:19–23

    Article  PubMed  Google Scholar 

  54. Vanaie A, Shahidi S, Iraj B, Siadat ZD, Kabirzade M, Shakiba F et al (2019) Curcumin as a major active component of turmeric attenuates proteinuria in patients with overt diabetic nephropathy. J Res Med Sci 24:77. https://doi.org/10.4103/jrms.JRMS_1055_18

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Cachofeiro V, Goicochea M, De Vinuesa SG, Oubiña P, Lahera V, Luño J (2008) Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease: New strategies to prevent cardiovascular risk in chronic kidney disease. Kidney Int 74:S4–S9

    Article  CAS  Google Scholar 

  56. Hallajzadeh J, Milajerdi A, Kolahdooz F, Amirani E, Mirzaei H, Asemi Z (2019) The effects of curcumin supplementation on endothelial function: a systematic review and meta-analysis of randomized controlled trials. Phytother Res 33(11):2989–2995

    Article  CAS  PubMed  Google Scholar 

  57. Qin S, Huang L, Gong J, Shen S, Huang J, Ren H et al (2017) Efficacy and safety of turmeric and curcumin in lowering blood lipid levels in patients with cardiovascular risk factors: a meta-analysis of randomized controlled trials. J Nutr 16(1):68. https://doi.org/10.1186/s12937-017-0293-y

    Article  CAS  Google Scholar 

  58. Jurenka JS (2009) Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research. Altern Med Rev 14(2):141–153

    PubMed  Google Scholar 

  59. Camacho-Barquero L, Villegas I, Sánchez-Calvo JM, Talero E, Sánchez-Fidalgo S, Motilva V et al (2007) Curcumin, a Curcuma longa constituent, acts on MAPK p38 pathway modulating COX-2 and iNOS expression in chronic experimental colitis. Int Immunopharmacol 7(3):333–342

    Article  CAS  PubMed  Google Scholar 

  60. Cho JW, Lee KS, Kim CW (2007) Curcumin attenuates the expression of IL-1β, IL-6, and TNF-α as well as cyclin E in TNF-α-treated HaCaT cells; NF-κB and MAPKs as potential upstream targets. Int J Mol Med 19(3):469–474

    CAS  PubMed  Google Scholar 

  61. Goel A, Kunnumakkara AB, Aggarwal BB (2008) Curcumin as “Curecumin”: from kitchen to clinic. Biochem Pharmacol 75(4):787–809

    Article  CAS  PubMed  Google Scholar 

  62. Ilbey YO, Ozbek E, Cekmen M, Simsek A, Otunctemur A, Somay A (2009) Protective effect of curcumin in cisplatin-induced oxidative injury in rat testis: mitogen-activated protein kinase and nuclear factor-kappa B signaling pathways. Hum Reprod 24(7):1717–1725

    Article  CAS  PubMed  Google Scholar 

  63. Marín YE, Wall BA, Wang S, Namkoong J, Martino JJ, Suh J et al (2007) Curcumin downregulates the constitutive activity of NF-κB and induces apoptosis in novel mouse melanoma cells. Melanoma Res 17(5):274–283

    Article  PubMed  CAS  Google Scholar 

  64. Bachmeier BE, Mohrenz IV, Mirisola V, Schleicher E, Romeo F, Höhneke C et al (2008) Curcumin downregulates the inflammatory cytokines CXCL1 and-2 in breast cancer cells via NFκB. Carcinogenesis 29(4):779–789

    Article  CAS  PubMed  Google Scholar 

  65. Pan Y, Zhang X, Wang Y, Cai L, Ren L, Tang L et al (2013) Targeting JNK by a new curcumin analog to inhibit NF-kB-mediated expression of cell adhesion molecules attenuates renal macrophage infiltration and injury in diabetic mice. PLoS One 8(11):e79084. https://doi.org/10.1371/journal.pone.0079084. eCollection 2013

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Hong J, Bose M, Ju J, Ryu J-H, Chen X, Sang S et al (2004) Modulation of arachidonic acid metabolism by curcumin and related β-diketone derivatives: effects on cytosolic phospholipase A 2, cyclooxygenases and 5-lipoxygenase. Carcinogenesis 25(9):1671–1679

    Article  CAS  PubMed  Google Scholar 

  67. Jiang H, Deng C-S, Zhang M, Xia J (2006) Curcumin-attenuated trinitrobenzene sulphonic acid induces chronic colitis by inhibiting expression of cyclooxygenase-2. World J Gastroenterol 12(24):3848–3853

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Yang C, Zhang X, Fan H, Liu Y (2009) Curcumin upregulates transcription factor Nrf2, HO-1 expression and protects rat brains against focal ischemia. Brain Res 1282:133–141

    Article  CAS  PubMed  Google Scholar 

  69. Balogun E, Hoque M, Gong P, Killeen E, Green CJ, Foresti R et al (2003) Curcumin activates the haem oxygenase-1 gene via regulation of Nrf2 and the antioxidant-responsive element. Biochem J 371(3):887–895

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Pizzo P, Scapin C, Vitadello M, Florean C, Gorza L (2010) Grp94 acts as a mediator of curcumin-induced antioxidant defence in myogenic cells. J Cell Mol Med 14(4):970–981

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Lopresti AL (2018) The problem of curcumin and its bioavailability: could its gastrointestinal influence contribute to its overall health-enhancing effects? Adv Nutr 9(1):41–50

    Article  PubMed  PubMed Central  Google Scholar 

  72. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB (2007) Bioavailability of curcumin: problems and promises. Mol Pharm 4(6):807–818

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Food Security Research Center, Department of Community Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran

    Mohammad Bagherniya, Mohammad Hossein Rouhani & Gholamreza Askari

  2. School of Nutrition Sciences and Food Technology, Kermanshah University of Medical Sciences, Kermanshah, Iran

    Davood Soleimani

  3. Department of Academic Diabetes, Endocrinology and Metabolism, Hull York Medical School, University of Hull, Hull, UK

    Thozhukat Sathyapalan

  4. Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran

    Amirhossein Sahebkar

  5. Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

    Amirhossein Sahebkar

  6. Halal Research Center of IRI, FDA, Tehran, Iran

    Amirhossein Sahebkar

  7. Polish Mother’s Memorial Hospital Research Institute (PMMHRI), Lodz, Poland

    Amirhossein Sahebkar

Authors
  1. Mohammad Bagherniya
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Davood Soleimani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mohammad Hossein Rouhani
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gholamreza Askari
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Thozhukat Sathyapalan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Amirhossein Sahebkar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Amirhossein Sahebkar .

Editor information

Editors and Affiliations

  1. University of Campinas, Sao Paulo, Brazil

    Paul C. Guest

Rights and permissions

Reprints and permissions

Copyright information

© 2021 The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Bagherniya, M., Soleimani, D., Rouhani, M.H., Askari, G., Sathyapalan, T., Sahebkar, A. (2021). The Use of Curcumin for the Treatment of Renal Disorders: A Systematic Review of Randomized Controlled Trials. In: Guest, P.C. (eds) Studies on Biomarkers and New Targets in Aging Research in Iran. Advances in Experimental Medicine and Biology(), vol 1291. Springer, Cham. https://doi.org/10.1007/978-3-030-56153-6_19

Download citation

Publish with us

Policies and ethics

Search

Navigation